Turn on cookies to sign in
Signing in saves your progress to your Curie account. We can only do that with cookies on — turn them on to continue.

An erectile dysfunction drug repurposed for Alzheimer's delivered mixed but intriguing results. Mirodenafil (AR1001) missed its primary endpoint in the overall trial population but slowed cognitive decline by 31% in patients not already on standard Alzheimer's medications. Researchers say the findings are encouraging enough to keep the drug in play.
A phase III trial called POLARIS-AD tested mirodenafil (AR1001) — an oral drug from the same family as Viagra — in over 1,500 amyloid-positive patients with early Alzheimer's disease. The drug, which works by boosting blood flow to the brain, missed its primary endpoint in the overall study population. However, in a prespecified subgroup of patients not taking standard Alzheimer's medications (acetylcholinesterase inhibitors or memantine), it showed a statistically significant 31% slowing of cognitive decline over 52 weeks.
Secondary cognitive and functional measures also trended in favor of AR1001 across both groups, with Mini-Mental State Examination scores showing nominally significant improvement in the monotherapy subgroup. Biomarker data confirmed the drug was engaging its intended target in the brain.
By the Numbers:
Why it matters: With few effective Alzheimer's treatments available, a repurposed drug that's already approved and well-understood could offer a faster path to patients — especially for those not on existing therapies. The ongoing open-label extension and further analyses will be critical in determining next steps.